English

SONOMA PHARMACEUTICALS, INC.

EDGAR

SNOA Quarterly report (10-Q) · filed 2026-08-06

Annual consolidated revenue for 2026: about USD 19.53M, using the latest reported figures. The previous period, 2025, was about USD 14.29M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

6.41 million USD

2027 Q1 · USD

Exact inputs and evidence

Revenue: 6406000 USD Source

Operating margin

-0.62%

2027 Q1 · %

Exact inputs and evidence

Operating Income: -40000 USD Source
Revenue: 6406000 USD Source

Operating cash flow

-649 thousand USD

2027 Q1 · USD

Exact inputs and evidence

Operating Cash Flow: -649000 USD Source

Free cash flow

-651 thousand USD

2027 Q1 · USD

Exact inputs and evidence

Operating Cash Flow: -649000 USD Source
Capital Expenditure: 2000 USD Source

Cash and cash equivalents: 5.34 million USD 2026-06-30 Source
Exact value

5338000 USD
Long-term debt including current maturities: 334 thousand USD 2019-03-31 Source
Exact value

334000 USD
Shares outstanding: 4.79 million shares 2026-06-30 Source
Exact value

4785801 shares

Reported share-count change

191.33% · 3.14 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

1642765 shares · 2025-06-30· Source
4785801 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

21.9 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 5604000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 4349000 USD · 2025-10-01 – 2025-12-31 Source
Revenue: 19529000 USD · 2025-04-01 – 2026-03-31 Source
Revenue: 13968000 USD · 2025-04-01 – 2025-12-31 Source
Revenue: 6406000 USD · 2026-04-01 – 2026-06-30 Source

Net income

-2.26 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -534000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -819000 USD · 2025-10-01 – 2025-12-31 Source
Net income: -3175000 USD · 2025-04-01 – 2026-03-31 Source
Net income: -2594000 USD · 2025-04-01 – 2025-12-31 Source
Net income: -330000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-2.57 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -2650000 USD · 2025-04-01 – 2025-09-30 Source
Operating cash flow: -2015000 USD · 2025-04-01 – 2025-06-30 Source
Operating cash flow: -3414000 USD · 2025-04-01 – 2025-12-31 Source
Operating cash flow: -2650000 USD · 2025-04-01 – 2025-09-30 Source
Operating cash flow: -3933000 USD · 2025-04-01 – 2026-03-31 Source
Operating cash flow: -3414000 USD · 2025-04-01 – 2025-12-31 Source
Operating cash flow: -649000 USD · 2026-04-01 – 2026-06-30 Source

Capital expenditure

88 thousand USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 116000 USD · 2025-04-01 – 2025-09-30 Source
Capital expenditure: 106000 USD · 2025-04-01 – 2025-06-30 Source
Capital expenditure: 163000 USD · 2025-04-01 – 2025-12-31 Source
Capital expenditure: 116000 USD · 2025-04-01 – 2025-09-30 Source
Capital expenditure: 192000 USD · 2025-04-01 – 2026-03-31 Source
Capital expenditure: 163000 USD · 2025-04-01 – 2025-12-31 Source
Capital expenditure: 2000 USD · 2026-04-01 – 2026-06-30 Source

Free cash flow

-2.66 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -2650000 USD · 2025-04-01 – 2025-09-30 Source
Operating cash flow: -2015000 USD · 2025-04-01 – 2025-06-30 Source
Operating cash flow: -3414000 USD · 2025-04-01 – 2025-12-31 Source
Operating cash flow: -2650000 USD · 2025-04-01 – 2025-09-30 Source
Operating cash flow: -3933000 USD · 2025-04-01 – 2026-03-31 Source
Operating cash flow: -3414000 USD · 2025-04-01 – 2025-12-31 Source
Operating cash flow: -649000 USD · 2026-04-01 – 2026-06-30 Source
Capital expenditure: 116000 USD · 2025-04-01 – 2025-09-30 Source
Capital expenditure: 106000 USD · 2025-04-01 – 2025-06-30 Source
Capital expenditure: 163000 USD · 2025-04-01 – 2025-12-31 Source
Capital expenditure: 116000 USD · 2025-04-01 – 2025-09-30 Source
Capital expenditure: 192000 USD · 2025-04-01 – 2026-03-31 Source
Capital expenditure: 163000 USD · 2025-04-01 – 2025-12-31 Source
Capital expenditure: 2000 USD · 2026-04-01 – 2026-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-06.

Financial data available through: 2026-03-31.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2026-03-31
Operating income: 11 of 11 periods available· newest 2026-03-31
Net income: 11 of 11 periods available· newest 2026-03-31
Operating cash flow: 11 of 11 periods available· newest 2026-03-31
Capital expenditure: 11 of 11 periods available· newest 2026-03-31
Total assets: 11 of 11 periods available· newest 2026-03-31
Total liabilities: 11 of 11 periods available· newest 2026-03-31
Current assets: 11 of 11 periods available· newest 2026-03-31
Current liabilities: 11 of 11 periods available· newest 2026-03-31
Cash and cash equivalents: 11 of 11 periods available· newest 2026-03-31
Long-term debt including current maturities: 3 of 11 periods available· newest 2019-03-31
Shares outstanding: 11 of 11 periods available· newest 2026-03-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+36.7%

Prior period

USD 14.29 million

2024-04-01 – 2025-03-31
Current period

USD 19.53 million

2025-04-01 – 2026-03-31

Exact inputs and evidence

19529000 − 14288000 = 5241000 USD

14288000 USD · 2024-04-01 – 2025-03-31
Inspect prior input Prior source
19529000 USD · 2025-04-01 – 2026-03-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · SONOMA PHARMACEUTICALS, INC. · 2026-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Year-over-year change in Revenue: 5241000 USD Concept: fundies:Revenue Period: 2025-04-01 to 2026-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 19529000 USD (2025-04-01 to 2026-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316826004871/sonoma_i10k-033126.htm#977378 Filing: 000168316826004871 Input fundies:Revenue: 14288000 USD (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316826004871/sonoma_i10k-033126.htm#977993 Filing: 000168316826004871
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 282,000

Prior period

−USD 3.46 million

2024-04-01 – 2025-03-31
Current period

−USD 3.18 million

2025-04-01 – 2026-03-31

Exact inputs and evidence

-3175000 − -3457000 = 282000 USD

-3457000 USD · 2024-04-01 – 2025-03-31
Inspect prior input Prior source
-3175000 USD · 2025-04-01 – 2026-03-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · SONOMA PHARMACEUTICALS, INC. · 2026-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Year-over-year change in Net income: 282000 USD Concept: fundies:NetIncome Period: 2025-04-01 to 2026-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -3175000 USD (2025-04-01 to 2026-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316826004871/sonoma_i10k-033126.htm#685684 Filing: 000168316826004871 Input fundies:NetIncome: -3457000 USD (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316826004871/sonoma_i10k-033126.htm#686175 Filing: 000168316826004871
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 3.85 million

Prior period

−USD 88,000

2024-04-01 – 2025-03-31
Current period

−USD 3.93 million

2025-04-01 – 2026-03-31

Exact inputs and evidence

-3933000 − -88000 = -3845000 USD

-88000 USD · 2024-04-01 – 2025-03-31
Inspect prior input Prior source
-3933000 USD · 2025-04-01 – 2026-03-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · SONOMA PHARMACEUTICALS, INC. · 2026-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Year-over-year change in Operating cash flow: -3845000 USD Concept: fundies:OperatingCashFlow Period: 2025-04-01 to 2026-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -3933000 USD (2025-04-01 to 2026-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316826004871/sonoma_i10k-033126.htm#609105 Filing: 000168316826004871 Input fundies:OperatingCashFlow: -88000 USD (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316826004871/sonoma_i10k-033126.htm#609511 Filing: 000168316826004871
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+140%

Prior period

USD 80,000

2024-04-01 – 2025-03-31
Current period

USD 192,000

2025-04-01 – 2026-03-31

Exact inputs and evidence

192000 − 80000 = 112000 USD

80000 USD · 2024-04-01 – 2025-03-31
Inspect prior input Prior source
192000 USD · 2025-04-01 – 2026-03-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · SONOMA PHARMACEUTICALS, INC. · 2026-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Year-over-year change in Capital expenditure: 112000 USD Concept: fundies:CapitalExpenditure Period: 2025-04-01 to 2026-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 192000 USD (2025-04-01 to 2026-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316826004871/sonoma_i10k-033126.htm#582508 Filing: 000168316826004871 Input fundies:CapitalExpenditure: 80000 USD (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316826004871/sonoma_i10k-033126.htm#582967 Filing: 000168316826004871
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2026 2025-04-01 – 2026-03-31

Revenue USD 19.53 million 100% of revenue
Cost of revenue USD 12.11 million 62% of revenue
Operating expenses USD 9.88 million 51% of revenue
Operating income −USD 2.46 million −13% of revenue
Tax, interest and other Derived USD 714,000 3.7% of revenue
Net income −USD 3.18 million −16% of revenue

Cash

Operating cash flow −USD 3.93 million −20% of revenue
Capital expenditure USD 192,000 1% of revenue
Free cash flow Derived −USD 4.13 million −21% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2017 Operating loss: operating costs were 201% of revenue.
2018 Operating loss: operating costs were 185% of revenue.
2019 Operating loss: operating costs were 159% of revenue.
2020 Operating loss: operating costs were 141% of revenue.
2021 Operating loss: operating costs were 119% of revenue.
2022 Operating loss: operating costs were 147% of revenue.
2023 Operating loss: operating costs were 134% of revenue.
2024 Operating loss: operating costs were 137% of revenue.
2025 Operating loss: operating costs were 126% of revenue.
2026 Operating loss: operating costs were 113% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2017 2016-04-01 – 2017-03-31	12825000	25799000 Derived	-12974000	-22248000 Derived	9274000	-8561000 Derived	Source 2016-04-01 – 2017-03-31: 12825000 USD Inspect Revenue Open source 2016-04-01 – 2017-03-31: -12974000 USD Inspect Operating Income Open source 2016-04-01 – 2017-03-31: 9274000 USD Inspect Net Income Open source 2016-04-01 – 2017-03-31: -8167000 USD Inspect Operating Cash Flow Open source 2016-04-01 – 2017-03-31: 394000 USD Inspect Capital Expenditure Open source
2018 2017-04-01 – 2018-03-31	16658000	30847000 Derived	-14189000	139000 Derived	-14328000	-12626000 Derived	Source 2017-04-01 – 2018-03-31: 16658000 USD Inspect Revenue Open source 2017-04-01 – 2018-03-31: -14189000 USD Inspect Operating Income Open source 2017-04-01 – 2018-03-31: -14328000 USD Inspect Net Income Open source 2017-04-01 – 2018-03-31: -12439000 USD Inspect Operating Cash Flow Open source 2017-04-01 – 2018-03-31: 187000 USD Inspect Capital Expenditure Open source
2019 2018-04-01 – 2019-03-31	18970000	30228000 Derived	-11258000	540000 Derived	-11798000	-11817000 Derived	Source 2018-04-01 – 2019-03-31: 18970000 USD Inspect Revenue Open source 2018-04-01 – 2019-03-31: -11258000 USD Inspect Operating Income Open source 2018-04-01 – 2019-03-31: -11798000 USD Inspect Net Income Open source 2018-04-01 – 2019-03-31: -11717000 USD Inspect Operating Cash Flow Open source 2018-04-01 – 2019-03-31: 100000 USD Inspect Capital Expenditure Open source
2020 2019-04-01 – 2020-03-31	17928000	25318000 Derived	-7390000	-4082000 Derived	-3308000	-4797000 Derived	Source 2019-04-01 – 2020-03-31: 17928000 USD Inspect Revenue Open source 2019-04-01 – 2020-03-31: -7390000 USD Inspect Operating Income Open source 2019-04-01 – 2020-03-31: -3308000 USD Inspect Net Income Open source 2019-04-01 – 2020-03-31: -4591000 USD Inspect Operating Cash Flow Open source 2019-04-01 – 2020-03-31: 206000 USD Inspect Capital Expenditure Open source
2021 2020-04-01 – 2021-03-31	18629000	22078000 Derived	-3449000	501000 Derived	-3950000	-3557000 Derived	Source 2020-04-01 – 2021-03-31: 18629000 USD Inspect Revenue Open source 2020-04-01 – 2021-03-31: -3449000 USD Inspect Operating Income Open source 2020-04-01 – 2021-03-31: -3950000 USD Inspect Net Income Open source 2020-04-01 – 2021-03-31: -3378000 USD Inspect Operating Cash Flow Open source 2020-04-01 – 2021-03-31: 179000 USD Inspect Capital Expenditure Open source
2022 2021-04-01 – 2022-03-31	12628000	18515000 Derived	-5887000	-801000 Derived	-5086000	-4385000 Derived	Source 2021-04-01 – 2022-03-31: 12628000 USD Inspect Revenue Open source 2021-04-01 – 2022-03-31: -5887000 USD Inspect Operating Income Open source 2021-04-01 – 2022-03-31: -5086000 USD Inspect Net Income Open source 2021-04-01 – 2022-03-31: -4248000 USD Inspect Operating Cash Flow Open source 2021-04-01 – 2022-03-31: 137000 USD Inspect Capital Expenditure Open source
2023 2022-04-01 – 2023-03-31	13272000	17842000 Derived	-4570000	581000 Derived	-5151000	-6421000 Derived	Source 2022-04-01 – 2023-03-31: 13272000 USD Inspect Revenue Open source 2022-04-01 – 2023-03-31: -4570000 USD Inspect Operating Income Open source 2022-04-01 – 2023-03-31: -5151000 USD Inspect Net Income Open source 2022-04-01 – 2023-03-31: -6152000 USD Inspect Operating Cash Flow Open source 2022-04-01 – 2023-03-31: 269000 USD Inspect Capital Expenditure Open source
2024 2023-04-01 – 2024-03-31	12735000	17436000 Derived	-4701000	134000 Derived	-4835000	-2400000 Derived	Source 2023-04-01 – 2024-03-31: 12735000 USD Inspect Revenue Open source 2023-04-01 – 2024-03-31: -4701000 USD Inspect Operating Income Open source 2023-04-01 – 2024-03-31: -4835000 USD Inspect Net Income Open source 2023-04-01 – 2024-03-31: -2398000 USD Inspect Operating Cash Flow Open source 2023-04-01 – 2024-03-31: 2000 USD Inspect Capital Expenditure Open source
2025 2024-04-01 – 2025-03-31	14288000	17998000 Derived	-3710000	-253000 Derived	-3457000	-168000 Derived	Source 2024-04-01 – 2025-03-31: 14288000 USD Inspect Revenue Open source 2024-04-01 – 2025-03-31: -3710000 USD Inspect Operating Income Open source 2024-04-01 – 2025-03-31: -3457000 USD Inspect Net Income Open source 2024-04-01 – 2025-03-31: -88000 USD Inspect Operating Cash Flow Open source 2024-04-01 – 2025-03-31: 80000 USD Inspect Capital Expenditure Open source
2026 2025-04-01 – 2026-03-31	19529000	21990000 Derived	-2461000	714000 Derived	-3175000	-4125000 Derived	Source 2025-04-01 – 2026-03-31: 19529000 USD Inspect Revenue Open source 2025-04-01 – 2026-03-31: -2461000 USD Inspect Operating Income Open source 2025-04-01 – 2026-03-31: -3175000 USD Inspect Net Income Open source 2025-04-01 – 2026-03-31: -3933000 USD Inspect Operating Cash Flow Open source 2025-04-01 – 2026-03-31: 192000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 19.5M 2026

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-03-31	Revenue	12825000	Revenue: 12825000 Open source
20182018-03-31	Revenue	16658000	Revenue: 16658000 Open source
20192019-03-31	Revenue	18970000	Revenue: 18970000 Open source
20202020-03-31	Revenue	17928000	Revenue: 17928000 Open source
20212021-03-31	Revenue	18629000	Revenue: 18629000 Open source
20222022-03-31	Revenue	12628000	Revenue: 12628000 Open source
20232023-03-31	Revenue	13272000	Revenue: 13272000 Open source
20242024-03-31	Revenue	12735000	Revenue: 12735000 Open source
20252025-03-31	Revenue	14288000	Revenue: 14288000 Open source
20262026-03-31	Revenue	19529000	Revenue: 19529000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

36.7% 2026

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20172017-03-31	Year over year	36.9%	Revenue: 12825000 Open source Revenue: 9369000 Open source
20182018-03-31	Year over year	29.9%	Revenue: 16658000 Open source Revenue: 12825000 Open source
20192019-03-31	Year over year	13.9%	Revenue: 18970000 Open source Revenue: 16658000 Open source
20202020-03-31	Year over year	-5.5%	Revenue: 17928000 Open source Revenue: 18970000 Open source
20212021-03-31	Year over year	3.9%	Revenue: 18629000 Open source Revenue: 17928000 Open source
20222022-03-31	Year over year	-32.2%	Revenue: 12628000 Open source Revenue: 18629000 Open source
20232023-03-31	Year over year	5.1%	Revenue: 13272000 Open source Revenue: 12628000 Open source
20242024-03-31	Year over year	-4%	Revenue: 12735000 Open source Revenue: 13272000 Open source
20252025-03-31	Year over year	12.2%	Revenue: 14288000 Open source Revenue: 12735000 Open source
20262026-03-31	Year over year	36.7%	Revenue: 19529000 Open source Revenue: 14288000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -12.6% 2026

Net margin -16.3% 2026

Free cash flow margin -21.1% 2026

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20172017-03-31	Operating margin	-101.2%	Operating Income: -12974000 Open source Revenue: 12825000 Open source
20182018-03-31	Operating margin	-85.2%	Operating Income: -14189000 Open source Revenue: 16658000 Open source
20192019-03-31	Operating margin	-59.3%	Operating Income: -11258000 Open source Revenue: 18970000 Open source
20202020-03-31	Operating margin	-41.2%	Operating Income: -7390000 Open source Revenue: 17928000 Open source
20212021-03-31	Operating margin	-18.5%	Operating Income: -3449000 Open source Revenue: 18629000 Open source
20222022-03-31	Operating margin	-46.6%	Operating Income: -5887000 Open source Revenue: 12628000 Open source
20232023-03-31	Operating margin	-34.4%	Operating Income: -4570000 Open source Revenue: 13272000 Open source
20242024-03-31	Operating margin	-36.9%	Operating Income: -4701000 Open source Revenue: 12735000 Open source
20252025-03-31	Operating margin	-26%	Operating Income: -3710000 Open source Revenue: 14288000 Open source
20262026-03-31	Operating margin	-12.6%	Operating Income: -2461000 Open source Revenue: 19529000 Open source
20172017-03-31	Net margin	72.3%	Net Income: 9274000 Open source Revenue: 12825000 Open source
20182018-03-31	Net margin	-86%	Net Income: -14328000 Open source Revenue: 16658000 Open source
20192019-03-31	Net margin	-62.2%	Net Income: -11798000 Open source Revenue: 18970000 Open source
20202020-03-31	Net margin	-18.5%	Net Income: -3308000 Open source Revenue: 17928000 Open source
20212021-03-31	Net margin	-21.2%	Net Income: -3950000 Open source Revenue: 18629000 Open source
20222022-03-31	Net margin	-40.3%	Net Income: -5086000 Open source Revenue: 12628000 Open source
20232023-03-31	Net margin	-38.8%	Net Income: -5151000 Open source Revenue: 13272000 Open source
20242024-03-31	Net margin	-38%	Net Income: -4835000 Open source Revenue: 12735000 Open source
20252025-03-31	Net margin	-24.2%	Net Income: -3457000 Open source Revenue: 14288000 Open source
20262026-03-31	Net margin	-16.3%	Net Income: -3175000 Open source Revenue: 19529000 Open source
20172017-03-31	Free cash flow margin	-66.8%	Revenue: 12825000 Open source Operating Cash Flow: -8167000 Open source Capital Expenditure: 394000 Open source
20182018-03-31	Free cash flow margin	-75.8%	Revenue: 16658000 Open source Operating Cash Flow: -12439000 Open source Capital Expenditure: 187000 Open source
20192019-03-31	Free cash flow margin	-62.3%	Revenue: 18970000 Open source Operating Cash Flow: -11717000 Open source Capital Expenditure: 100000 Open source
20202020-03-31	Free cash flow margin	-26.8%	Revenue: 17928000 Open source Operating Cash Flow: -4591000 Open source Capital Expenditure: 206000 Open source
20212021-03-31	Free cash flow margin	-19.1%	Revenue: 18629000 Open source Operating Cash Flow: -3378000 Open source Capital Expenditure: 179000 Open source
20222022-03-31	Free cash flow margin	-34.7%	Revenue: 12628000 Open source Operating Cash Flow: -4248000 Open source Capital Expenditure: 137000 Open source
20232023-03-31	Free cash flow margin	-48.4%	Revenue: 13272000 Open source Operating Cash Flow: -6152000 Open source Capital Expenditure: 269000 Open source
20242024-03-31	Free cash flow margin	-18.8%	Revenue: 12735000 Open source Operating Cash Flow: -2398000 Open source Capital Expenditure: 2000 Open source
20252025-03-31	Free cash flow margin	-1.2%	Revenue: 14288000 Open source Operating Cash Flow: -88000 Open source Capital Expenditure: 80000 Open source
20262026-03-31	Free cash flow margin	-21.1%	Revenue: 19529000 Open source Operating Cash Flow: -3933000 Open source Capital Expenditure: 192000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -3.9M 2026

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-03-31	Operating cash flow	-8167000	Operating Cash Flow: -8167000 Open source
20182018-03-31	Operating cash flow	-12439000	Operating Cash Flow: -12439000 Open source
20192019-03-31	Operating cash flow	-11717000	Operating Cash Flow: -11717000 Open source
20202020-03-31	Operating cash flow	-4591000	Operating Cash Flow: -4591000 Open source
20212021-03-31	Operating cash flow	-3378000	Operating Cash Flow: -3378000 Open source
20222022-03-31	Operating cash flow	-4248000	Operating Cash Flow: -4248000 Open source
20232023-03-31	Operating cash flow	-6152000	Operating Cash Flow: -6152000 Open source
20242024-03-31	Operating cash flow	-2398000	Operating Cash Flow: -2398000 Open source
20252025-03-31	Operating cash flow	-88000	Operating Cash Flow: -88000 Open source
20262026-03-31	Operating cash flow	-3933000	Operating Cash Flow: -3933000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -4.1M 2026

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-03-31	Free cash flow	-8561000	Operating Cash Flow: -8167000 Open source Capital Expenditure: 394000 Open source
20182018-03-31	Free cash flow	-12626000	Operating Cash Flow: -12439000 Open source Capital Expenditure: 187000 Open source
20192019-03-31	Free cash flow	-11817000	Operating Cash Flow: -11717000 Open source Capital Expenditure: 100000 Open source
20202020-03-31	Free cash flow	-4797000	Operating Cash Flow: -4591000 Open source Capital Expenditure: 206000 Open source
20212021-03-31	Free cash flow	-3557000	Operating Cash Flow: -3378000 Open source Capital Expenditure: 179000 Open source
20222022-03-31	Free cash flow	-4385000	Operating Cash Flow: -4248000 Open source Capital Expenditure: 137000 Open source
20232023-03-31	Free cash flow	-6421000	Operating Cash Flow: -6152000 Open source Capital Expenditure: 269000 Open source
20242024-03-31	Free cash flow	-2400000	Operating Cash Flow: -2398000 Open source Capital Expenditure: 2000 Open source
20252025-03-31	Free cash flow	-168000	Operating Cash Flow: -88000 Open source Capital Expenditure: 80000 Open source
20262026-03-31	Free cash flow	-4125000	Operating Cash Flow: -3933000 Open source Capital Expenditure: 192000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

77.8% 2026

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20172017-03-31	Liabilities / assets	15.8%	Total Liabilities: 4028000 Open source Total Assets: 25459000 Open source
20182018-03-31	Liabilities / assets	20.2%	Total Liabilities: 3880000 Open source Total Assets: 19206000 Open source
20192019-03-31	Liabilities / assets	27.4%	Total Liabilities: 3959000 Open source Total Assets: 14448000 Open source
20202020-03-31	Liabilities / assets	61.4%	Total Liabilities: 8937000 Open source Total Assets: 14561000 Open source
20212021-03-31	Liabilities / assets	64.2%	Total Liabilities: 9624000 Open source Total Assets: 14987000 Open source
20222022-03-31	Liabilities / assets	53.8%	Total Liabilities: 10148000 Open source Total Assets: 18845000 Open source
20232023-03-31	Liabilities / assets	50.9%	Total Liabilities: 8254000 Open source Total Assets: 16231000 Open source
20242024-03-31	Liabilities / assets	58.4%	Total Liabilities: 8603000 Open source Total Assets: 14740000 Open source
20252025-03-31	Liabilities / assets	67.8%	Total Liabilities: 9282000 Open source Total Assets: 13693000 Open source
20262026-03-31	Liabilities / assets	77.8%	Total Liabilities: 10865000 Open source Total Assets: 13960000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

2.5× 2026

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20172017-03-31	Current assets / current liabilities	6.89×	Current Assets: 22643000 Open source Current Liabilities: 3288000 Open source
20182018-03-31	Current assets / current liabilities	4.98×	Current Assets: 16254000 Open source Current Liabilities: 3261000 Open source
20192019-03-31	Current assets / current liabilities	3.48×	Current Assets: 12496000 Open source Current Liabilities: 3591000 Open source
20202020-03-31	Current assets / current liabilities	2.6×	Current Assets: 12283000 Open source Current Liabilities: 4729000 Open source
20212021-03-31	Current assets / current liabilities	3.18×	Current Assets: 12983000 Open source Current Liabilities: 4078000 Open source
20222022-03-31	Current assets / current liabilities	2.82×	Current Assets: 16430000 Open source Current Liabilities: 5819000 Open source
20232023-03-31	Current assets / current liabilities	3.71×	Current Assets: 13798000 Open source Current Liabilities: 3717000 Open source
20242024-03-31	Current assets / current liabilities	3.37×	Current Assets: 12548000 Open source Current Liabilities: 3719000 Open source
20252025-03-31	Current assets / current liabilities	3.09×	Current Assets: 12648000 Open source Current Liabilities: 4096000 Open source
20262026-03-31	Current assets / current liabilities	2.5×	Current Assets: 12100000 Open source Current Liabilities: 4832000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2017 2016-04-01 – 2017-03-31	USD 9.27 million Exact value Exact value: 9274000 USD 2016-04-01 – 2017-03-31: 9274000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SONOMA PHARMACEUTICALS, INC. · 2017-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Net Income: 9274000 USD Concept: fundies:NetIncome Period: 2016-04-01 to 2017-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083/explain?concept=fundies%3ANetIncome&period=2017-03-31&surface=latest&period_type=duration&start=2016-04-01&unit=USD&dimensions= Input fundies:NetIncome: 9274000 USD (2016-04-01 to 2017-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316818003037/snoa-20180331.xml#819870 Filing: 000168316818003037 The citation records this snapshot. The page link may show a newer release later.	−USD 8.17 million Exact value Exact value: -8167000 USD 2016-04-01 – 2017-03-31: -8167000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SONOMA PHARMACEUTICALS, INC. · 2017-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Operating Cash Flow: -8167000 USD Concept: fundies:OperatingCashFlow Period: 2016-04-01 to 2017-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083/explain?concept=fundies%3AOperatingCashFlow&period=2017-03-31&surface=latest&period_type=duration&start=2016-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -8167000 USD (2016-04-01 to 2017-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316818003037/snoa-20180331.xml#831793 Filing: 000168316818003037 The citation records this snapshot. The page link may show a newer release later.	USD 394,000 Exact value Exact value: 394000 USD 2016-04-01 – 2017-03-31: 394000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SONOMA PHARMACEUTICALS, INC. · 2017-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Capital Expenditure: 394000 USD Concept: fundies:CapitalExpenditure Period: 2016-04-01 to 2017-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083/explain?concept=fundies%3ACapitalExpenditure&period=2017-03-31&surface=latest&period_type=duration&start=2016-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 394000 USD (2016-04-01 to 2017-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316818003037/snoa-20180331.xml#831015 Filing: 000168316818003037 The citation records this snapshot. The page link may show a newer release later.	−USD 8.56 million Calculation and evidence -8167000 − 394000 USD Exact free cash flow: -8561000 USD 2016-04-01 – 2017-03-31: -8167000 USD · Inspect Operating Cash Flow · Source 2016-04-01 – 2017-03-31: 394000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SONOMA PHARMACEUTICALS, INC. · 2017-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Free cash flow: -8561000 USD Concept: free-cash-flow Period: 2016-04-01 to 2017-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -8167000 USD (2016-04-01 to 2017-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316818003037/snoa-20180331.xml#831793 Filing: 000168316818003037 Input fundies:CapitalExpenditure: 394000 USD (2016-04-01 to 2017-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316818003037/snoa-20180331.xml#831015 Filing: 000168316818003037 The citation records this snapshot. The page link may show a newer release later.
2018 2017-04-01 – 2018-03-31	−USD 14.33 million Exact value Exact value: -14328000 USD 2017-04-01 – 2018-03-31: -14328000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SONOMA PHARMACEUTICALS, INC. · 2018-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Net Income: -14328000 USD Concept: fundies:NetIncome Period: 2017-04-01 to 2018-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083/explain?concept=fundies%3ANetIncome&period=2018-03-31&surface=latest&period_type=duration&start=2017-04-01&unit=USD&dimensions= Input fundies:NetIncome: -14328000 USD (2017-04-01 to 2018-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316819002069/snoa-20190331.xml#184865 Filing: 000168316819002069 The citation records this snapshot. The page link may show a newer release later.	−USD 12.44 million Exact value Exact value: -12439000 USD 2017-04-01 – 2018-03-31: -12439000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SONOMA PHARMACEUTICALS, INC. · 2018-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Operating Cash Flow: -12439000 USD Concept: fundies:OperatingCashFlow Period: 2017-04-01 to 2018-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083/explain?concept=fundies%3AOperatingCashFlow&period=2018-03-31&surface=latest&period_type=duration&start=2017-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -12439000 USD (2017-04-01 to 2018-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316819002069/snoa-20190331.xml#176197 Filing: 000168316819002069 The citation records this snapshot. The page link may show a newer release later.	USD 187,000 Exact value Exact value: 187000 USD 2017-04-01 – 2018-03-31: 187000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SONOMA PHARMACEUTICALS, INC. · 2018-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Capital Expenditure: 187000 USD Concept: fundies:CapitalExpenditure Period: 2017-04-01 to 2018-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083/explain?concept=fundies%3ACapitalExpenditure&period=2018-03-31&surface=latest&period_type=duration&start=2017-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 187000 USD (2017-04-01 to 2018-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316819002069/snoa-20190331.xml#176608 Filing: 000168316819002069 The citation records this snapshot. The page link may show a newer release later.	−USD 12.63 million Calculation and evidence -12439000 − 187000 USD Exact free cash flow: -12626000 USD 2017-04-01 – 2018-03-31: -12439000 USD · Inspect Operating Cash Flow · Source 2017-04-01 – 2018-03-31: 187000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SONOMA PHARMACEUTICALS, INC. · 2018-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Free cash flow: -12626000 USD Concept: free-cash-flow Period: 2017-04-01 to 2018-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -12439000 USD (2017-04-01 to 2018-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316819002069/snoa-20190331.xml#176197 Filing: 000168316819002069 Input fundies:CapitalExpenditure: 187000 USD (2017-04-01 to 2018-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316819002069/snoa-20190331.xml#176608 Filing: 000168316819002069 The citation records this snapshot. The page link may show a newer release later.
2019 2018-04-01 – 2019-03-31	−USD 11.8 million Exact value Exact value: -11798000 USD 2018-04-01 – 2019-03-31: -11798000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SONOMA PHARMACEUTICALS, INC. · 2019-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Net Income: -11798000 USD Concept: fundies:NetIncome Period: 2018-04-01 to 2019-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083/explain?concept=fundies%3ANetIncome&period=2019-03-31&surface=latest&period_type=duration&start=2018-04-01&unit=USD&dimensions= Input fundies:NetIncome: -11798000 USD (2018-04-01 to 2019-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316820002234/snoa-20200331.xml#131888 Filing: 000168316820002234 The citation records this snapshot. The page link may show a newer release later.	−USD 11.72 million Exact value Exact value: -11717000 USD 2018-04-01 – 2019-03-31: -11717000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SONOMA PHARMACEUTICALS, INC. · 2019-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Operating Cash Flow: -11717000 USD Concept: fundies:OperatingCashFlow Period: 2018-04-01 to 2019-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083/explain?concept=fundies%3AOperatingCashFlow&period=2019-03-31&surface=latest&period_type=duration&start=2018-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -11717000 USD (2018-04-01 to 2019-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316820002234/snoa-20200331.xml#449694 Filing: 000168316820002234 The citation records this snapshot. The page link may show a newer release later.	USD 100,000 Exact value Exact value: 100000 USD 2018-04-01 – 2019-03-31: 100000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SONOMA PHARMACEUTICALS, INC. · 2019-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Capital Expenditure: 100000 USD Concept: fundies:CapitalExpenditure Period: 2018-04-01 to 2019-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083/explain?concept=fundies%3ACapitalExpenditure&period=2019-03-31&surface=latest&period_type=duration&start=2018-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 100000 USD (2018-04-01 to 2019-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316820002234/snoa-20200331.xml#449324 Filing: 000168316820002234 The citation records this snapshot. The page link may show a newer release later.	−USD 11.82 million Calculation and evidence -11717000 − 100000 USD Exact free cash flow: -11817000 USD 2018-04-01 – 2019-03-31: -11717000 USD · Inspect Operating Cash Flow · Source 2018-04-01 – 2019-03-31: 100000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SONOMA PHARMACEUTICALS, INC. · 2019-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Free cash flow: -11817000 USD Concept: free-cash-flow Period: 2018-04-01 to 2019-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -11717000 USD (2018-04-01 to 2019-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316820002234/snoa-20200331.xml#449694 Filing: 000168316820002234 Input fundies:CapitalExpenditure: 100000 USD (2018-04-01 to 2019-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316820002234/snoa-20200331.xml#449324 Filing: 000168316820002234 The citation records this snapshot. The page link may show a newer release later.
2020 2019-04-01 – 2020-03-31	−USD 3.31 million Exact value Exact value: -3308000 USD 2019-04-01 – 2020-03-31: -3308000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SONOMA PHARMACEUTICALS, INC. · 2020-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Net Income: -3308000 USD Concept: fundies:NetIncome Period: 2019-04-01 to 2020-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083/explain?concept=fundies%3ANetIncome&period=2020-03-31&surface=latest&period_type=duration&start=2019-04-01&unit=USD&dimensions= Input fundies:NetIncome: -3308000 USD (2019-04-01 to 2020-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316821002977/snoa-20210331.xml#161631 Filing: 000168316821002977 The citation records this snapshot. The page link may show a newer release later.	−USD 4.59 million Exact value Exact value: -4591000 USD 2019-04-01 – 2020-03-31: -4591000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SONOMA PHARMACEUTICALS, INC. · 2020-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Operating Cash Flow: -4591000 USD Concept: fundies:OperatingCashFlow Period: 2019-04-01 to 2020-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083/explain?concept=fundies%3AOperatingCashFlow&period=2020-03-31&surface=latest&period_type=duration&start=2019-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4591000 USD (2019-04-01 to 2020-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316821002977/snoa-20210331.xml#170894 Filing: 000168316821002977 The citation records this snapshot. The page link may show a newer release later.	USD 206,000 Exact value Exact value: 206000 USD 2019-04-01 – 2020-03-31: 206000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SONOMA PHARMACEUTICALS, INC. · 2020-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Capital Expenditure: 206000 USD Concept: fundies:CapitalExpenditure Period: 2019-04-01 to 2020-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083/explain?concept=fundies%3ACapitalExpenditure&period=2020-03-31&surface=latest&period_type=duration&start=2019-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 206000 USD (2019-04-01 to 2020-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316821002977/snoa-20210331.xml#178981 Filing: 000168316821002977 The citation records this snapshot. The page link may show a newer release later.	−USD 4.8 million Calculation and evidence -4591000 − 206000 USD Exact free cash flow: -4797000 USD 2019-04-01 – 2020-03-31: -4591000 USD · Inspect Operating Cash Flow · Source 2019-04-01 – 2020-03-31: 206000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SONOMA PHARMACEUTICALS, INC. · 2020-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Free cash flow: -4797000 USD Concept: free-cash-flow Period: 2019-04-01 to 2020-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -4591000 USD (2019-04-01 to 2020-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316821002977/snoa-20210331.xml#170894 Filing: 000168316821002977 Input fundies:CapitalExpenditure: 206000 USD (2019-04-01 to 2020-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316821002977/snoa-20210331.xml#178981 Filing: 000168316821002977 The citation records this snapshot. The page link may show a newer release later.
2021 2020-04-01 – 2021-03-31	−USD 3.95 million Exact value Exact value: -3950000 USD 2020-04-01 – 2021-03-31: -3950000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SONOMA PHARMACEUTICALS, INC. · 2021-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Net Income: -3950000 USD Concept: fundies:NetIncome Period: 2020-04-01 to 2021-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083/explain?concept=fundies%3ANetIncome&period=2021-03-31&surface=latest&period_type=duration&start=2020-04-01&unit=USD&dimensions= Input fundies:NetIncome: -3950000 USD (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316822004940/sonoma_i10k-033122.htm#781262 Filing: 000168316822004940 The citation records this snapshot. The page link may show a newer release later.	−USD 3.38 million Exact value Exact value: -3378000 USD 2020-04-01 – 2021-03-31: -3378000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SONOMA PHARMACEUTICALS, INC. · 2021-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Operating Cash Flow: -3378000 USD Concept: fundies:OperatingCashFlow Period: 2020-04-01 to 2021-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083/explain?concept=fundies%3AOperatingCashFlow&period=2021-03-31&surface=latest&period_type=duration&start=2020-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -3378000 USD (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316822004940/sonoma_i10k-033122.htm#674693 Filing: 000168316822004940 The citation records this snapshot. The page link may show a newer release later.	USD 179,000 Exact value Exact value: 179000 USD 2020-04-01 – 2021-03-31: 179000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SONOMA PHARMACEUTICALS, INC. · 2021-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Capital Expenditure: 179000 USD Concept: fundies:CapitalExpenditure Period: 2020-04-01 to 2021-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083/explain?concept=fundies%3ACapitalExpenditure&period=2021-03-31&surface=latest&period_type=duration&start=2020-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 179000 USD (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316822004940/sonoma_i10k-033122.htm#676186 Filing: 000168316822004940 The citation records this snapshot. The page link may show a newer release later.	−USD 3.56 million Calculation and evidence -3378000 − 179000 USD Exact free cash flow: -3557000 USD 2020-04-01 – 2021-03-31: -3378000 USD · Inspect Operating Cash Flow · Source 2020-04-01 – 2021-03-31: 179000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SONOMA PHARMACEUTICALS, INC. · 2021-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Free cash flow: -3557000 USD Concept: free-cash-flow Period: 2020-04-01 to 2021-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -3378000 USD (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316822004940/sonoma_i10k-033122.htm#674693 Filing: 000168316822004940 Input fundies:CapitalExpenditure: 179000 USD (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316822004940/sonoma_i10k-033122.htm#676186 Filing: 000168316822004940 The citation records this snapshot. The page link may show a newer release later.
2022 2021-04-01 – 2022-03-31	−USD 5.09 million Exact value Exact value: -5086000 USD 2021-04-01 – 2022-03-31: -5086000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SONOMA PHARMACEUTICALS, INC. · 2022-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Net Income: -5086000 USD Concept: fundies:NetIncome Period: 2021-04-01 to 2022-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083/explain?concept=fundies%3ANetIncome&period=2022-03-31&surface=latest&period_type=duration&start=2021-04-01&unit=USD&dimensions= Input fundies:NetIncome: -5086000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316823004323/sonoma_i10k-033123.htm#732671 Filing: 000168316823004323 The citation records this snapshot. The page link may show a newer release later.	−USD 4.25 million Exact value Exact value: -4248000 USD 2021-04-01 – 2022-03-31: -4248000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SONOMA PHARMACEUTICALS, INC. · 2022-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Operating Cash Flow: -4248000 USD Concept: fundies:OperatingCashFlow Period: 2021-04-01 to 2022-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083/explain?concept=fundies%3AOperatingCashFlow&period=2022-03-31&surface=latest&period_type=duration&start=2021-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4248000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316823004323/sonoma_i10k-033123.htm#660033 Filing: 000168316823004323 The citation records this snapshot. The page link may show a newer release later.	USD 137,000 Exact value Exact value: 137000 USD 2021-04-01 – 2022-03-31: 137000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SONOMA PHARMACEUTICALS, INC. · 2022-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Capital Expenditure: 137000 USD Concept: fundies:CapitalExpenditure Period: 2021-04-01 to 2022-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083/explain?concept=fundies%3ACapitalExpenditure&period=2022-03-31&surface=latest&period_type=duration&start=2021-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 137000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316823004323/sonoma_i10k-033123.htm#634022 Filing: 000168316823004323 The citation records this snapshot. The page link may show a newer release later.	−USD 4.39 million Calculation and evidence -4248000 − 137000 USD Exact free cash flow: -4385000 USD 2021-04-01 – 2022-03-31: -4248000 USD · Inspect Operating Cash Flow · Source 2021-04-01 – 2022-03-31: 137000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SONOMA PHARMACEUTICALS, INC. · 2022-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Free cash flow: -4385000 USD Concept: free-cash-flow Period: 2021-04-01 to 2022-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -4248000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316823004323/sonoma_i10k-033123.htm#660033 Filing: 000168316823004323 Input fundies:CapitalExpenditure: 137000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316823004323/sonoma_i10k-033123.htm#634022 Filing: 000168316823004323 The citation records this snapshot. The page link may show a newer release later.
2023 2022-04-01 – 2023-03-31	−USD 5.15 million Exact value Exact value: -5151000 USD 2022-04-01 – 2023-03-31: -5151000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SONOMA PHARMACEUTICALS, INC. · 2023-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Net Income: -5151000 USD Concept: fundies:NetIncome Period: 2022-04-01 to 2023-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083/explain?concept=fundies%3ANetIncome&period=2023-03-31&surface=latest&period_type=duration&start=2022-04-01&unit=USD&dimensions= Input fundies:NetIncome: -5151000 USD (2022-04-01 to 2023-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316824004275/sonoma_i10k-033124.htm#699550 Filing: 000168316824004275 The citation records this snapshot. The page link may show a newer release later.	−USD 6.15 million Exact value Exact value: -6152000 USD 2022-04-01 – 2023-03-31: -6152000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SONOMA PHARMACEUTICALS, INC. · 2023-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Operating Cash Flow: -6152000 USD Concept: fundies:OperatingCashFlow Period: 2022-04-01 to 2023-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083/explain?concept=fundies%3AOperatingCashFlow&period=2023-03-31&surface=latest&period_type=duration&start=2022-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -6152000 USD (2022-04-01 to 2023-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316824004275/sonoma_i10k-033124.htm#618948 Filing: 000168316824004275 The citation records this snapshot. The page link may show a newer release later.	USD 269,000 Exact value Exact value: 269000 USD 2022-04-01 – 2023-03-31: 269000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SONOMA PHARMACEUTICALS, INC. · 2023-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Capital Expenditure: 269000 USD Concept: fundies:CapitalExpenditure Period: 2022-04-01 to 2023-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083/explain?concept=fundies%3ACapitalExpenditure&period=2023-03-31&surface=latest&period_type=duration&start=2022-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 269000 USD (2022-04-01 to 2023-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316824004275/sonoma_i10k-033124.htm#594462 Filing: 000168316824004275 The citation records this snapshot. The page link may show a newer release later.	−USD 6.42 million Calculation and evidence -6152000 − 269000 USD Exact free cash flow: -6421000 USD 2022-04-01 – 2023-03-31: -6152000 USD · Inspect Operating Cash Flow · Source 2022-04-01 – 2023-03-31: 269000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SONOMA PHARMACEUTICALS, INC. · 2023-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Free cash flow: -6421000 USD Concept: free-cash-flow Period: 2022-04-01 to 2023-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -6152000 USD (2022-04-01 to 2023-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316824004275/sonoma_i10k-033124.htm#618948 Filing: 000168316824004275 Input fundies:CapitalExpenditure: 269000 USD (2022-04-01 to 2023-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316824004275/sonoma_i10k-033124.htm#594462 Filing: 000168316824004275 The citation records this snapshot. The page link may show a newer release later.
2024 2023-04-01 – 2024-03-31	−USD 4.84 million Exact value Exact value: -4835000 USD 2023-04-01 – 2024-03-31: -4835000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SONOMA PHARMACEUTICALS, INC. · 2024-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Net Income: -4835000 USD Concept: fundies:NetIncome Period: 2023-04-01 to 2024-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083/explain?concept=fundies%3ANetIncome&period=2024-03-31&surface=latest&period_type=duration&start=2023-04-01&unit=USD&dimensions= Input fundies:NetIncome: -4835000 USD (2023-04-01 to 2024-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316825004546/sonoma_i10k-033125.htm#728902 Filing: 000168316825004546 The citation records this snapshot. The page link may show a newer release later.	−USD 2.4 million Exact value Exact value: -2398000 USD 2023-04-01 – 2024-03-31: -2398000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SONOMA PHARMACEUTICALS, INC. · 2024-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Operating Cash Flow: -2398000 USD Concept: fundies:OperatingCashFlow Period: 2023-04-01 to 2024-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083/explain?concept=fundies%3AOperatingCashFlow&period=2024-03-31&surface=latest&period_type=duration&start=2023-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -2398000 USD (2023-04-01 to 2024-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316825004546/sonoma_i10k-033125.htm#650559 Filing: 000168316825004546 The citation records this snapshot. The page link may show a newer release later.	USD 2,000 Exact value Exact value: 2000 USD 2023-04-01 – 2024-03-31: 2000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SONOMA PHARMACEUTICALS, INC. · 2024-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Capital Expenditure: 2000 USD Concept: fundies:CapitalExpenditure Period: 2023-04-01 to 2024-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083/explain?concept=fundies%3ACapitalExpenditure&period=2024-03-31&surface=latest&period_type=duration&start=2023-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2000 USD (2023-04-01 to 2024-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316825004546/sonoma_i10k-033125.htm#624496 Filing: 000168316825004546 The citation records this snapshot. The page link may show a newer release later.	−USD 2.4 million Calculation and evidence -2398000 − 2000 USD Exact free cash flow: -2400000 USD 2023-04-01 – 2024-03-31: -2398000 USD · Inspect Operating Cash Flow · Source 2023-04-01 – 2024-03-31: 2000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SONOMA PHARMACEUTICALS, INC. · 2024-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Free cash flow: -2400000 USD Concept: free-cash-flow Period: 2023-04-01 to 2024-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -2398000 USD (2023-04-01 to 2024-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316825004546/sonoma_i10k-033125.htm#650559 Filing: 000168316825004546 Input fundies:CapitalExpenditure: 2000 USD (2023-04-01 to 2024-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316825004546/sonoma_i10k-033125.htm#624496 Filing: 000168316825004546 The citation records this snapshot. The page link may show a newer release later.
2025 2024-04-01 – 2025-03-31	−USD 3.46 million Exact value Exact value: -3457000 USD 2024-04-01 – 2025-03-31: -3457000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SONOMA PHARMACEUTICALS, INC. · 2025-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Net Income: -3457000 USD Concept: fundies:NetIncome Period: 2024-04-01 to 2025-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083/explain?concept=fundies%3ANetIncome&period=2025-03-31&surface=latest&period_type=duration&start=2024-04-01&unit=USD&dimensions= Input fundies:NetIncome: -3457000 USD (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316826004871/sonoma_i10k-033126.htm#686175 Filing: 000168316826004871 The citation records this snapshot. The page link may show a newer release later.	−USD 88,000 Exact value Exact value: -88000 USD 2024-04-01 – 2025-03-31: -88000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SONOMA PHARMACEUTICALS, INC. · 2025-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Operating Cash Flow: -88000 USD Concept: fundies:OperatingCashFlow Period: 2024-04-01 to 2025-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083/explain?concept=fundies%3AOperatingCashFlow&period=2025-03-31&surface=latest&period_type=duration&start=2024-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -88000 USD (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316826004871/sonoma_i10k-033126.htm#609511 Filing: 000168316826004871 The citation records this snapshot. The page link may show a newer release later.	USD 80,000 Exact value Exact value: 80000 USD 2024-04-01 – 2025-03-31: 80000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SONOMA PHARMACEUTICALS, INC. · 2025-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Capital Expenditure: 80000 USD Concept: fundies:CapitalExpenditure Period: 2024-04-01 to 2025-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083/explain?concept=fundies%3ACapitalExpenditure&period=2025-03-31&surface=latest&period_type=duration&start=2024-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 80000 USD (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316826004871/sonoma_i10k-033126.htm#582967 Filing: 000168316826004871 The citation records this snapshot. The page link may show a newer release later.	−USD 168,000 Calculation and evidence -88000 − 80000 USD Exact free cash flow: -168000 USD 2024-04-01 – 2025-03-31: -88000 USD · Inspect Operating Cash Flow · Source 2024-04-01 – 2025-03-31: 80000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SONOMA PHARMACEUTICALS, INC. · 2025-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Free cash flow: -168000 USD Concept: free-cash-flow Period: 2024-04-01 to 2025-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -88000 USD (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316826004871/sonoma_i10k-033126.htm#609511 Filing: 000168316826004871 Input fundies:CapitalExpenditure: 80000 USD (2024-04-01 to 2025-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316826004871/sonoma_i10k-033126.htm#582967 Filing: 000168316826004871 The citation records this snapshot. The page link may show a newer release later.
2026 2025-04-01 – 2026-03-31	−USD 3.18 million Exact value Exact value: -3175000 USD 2025-04-01 – 2026-03-31: -3175000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SONOMA PHARMACEUTICALS, INC. · 2026-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Net Income: -3175000 USD Concept: fundies:NetIncome Period: 2025-04-01 to 2026-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083/explain?concept=fundies%3ANetIncome&period=2026-03-31&surface=latest&period_type=duration&start=2025-04-01&unit=USD&dimensions= Input fundies:NetIncome: -3175000 USD (2025-04-01 to 2026-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316826004871/sonoma_i10k-033126.htm#685684 Filing: 000168316826004871 The citation records this snapshot. The page link may show a newer release later.	−USD 3.93 million Exact value Exact value: -3933000 USD 2025-04-01 – 2026-03-31: -3933000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SONOMA PHARMACEUTICALS, INC. · 2026-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Operating Cash Flow: -3933000 USD Concept: fundies:OperatingCashFlow Period: 2025-04-01 to 2026-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083/explain?concept=fundies%3AOperatingCashFlow&period=2026-03-31&surface=latest&period_type=duration&start=2025-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -3933000 USD (2025-04-01 to 2026-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316826004871/sonoma_i10k-033126.htm#609105 Filing: 000168316826004871 The citation records this snapshot. The page link may show a newer release later.	USD 192,000 Exact value Exact value: 192000 USD 2025-04-01 – 2026-03-31: 192000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SONOMA PHARMACEUTICALS, INC. · 2026-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Capital Expenditure: 192000 USD Concept: fundies:CapitalExpenditure Period: 2025-04-01 to 2026-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083/explain?concept=fundies%3ACapitalExpenditure&period=2026-03-31&surface=latest&period_type=duration&start=2025-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 192000 USD (2025-04-01 to 2026-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316826004871/sonoma_i10k-033126.htm#582508 Filing: 000168316826004871 The citation records this snapshot. The page link may show a newer release later.	−USD 4.13 million Calculation and evidence -3933000 − 192000 USD Exact free cash flow: -4125000 USD 2025-04-01 – 2026-03-31: -3933000 USD · Inspect Operating Cash Flow · Source 2025-04-01 – 2026-03-31: 192000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SONOMA PHARMACEUTICALS, INC. · 2026-03-31 SONOMA PHARMACEUTICALS, INC. (edgar:1367083) Free cash flow: -4125000 USD Concept: free-cash-flow Period: 2025-04-01 to 2026-03-31 Values: Latest reported Published: 2026-11-02T04:48:30Z Snapshot: 5fd9d552a9f4e81c0d32f05182deea890bcbbe3f51fa5b605f94ca865e7f0ac9 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367083?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -3933000 USD (2025-04-01 to 2026-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316826004871/sonoma_i10k-033126.htm#609105 Filing: 000168316826004871 Input fundies:CapitalExpenditure: 192000 USD (2025-04-01 to 2026-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367083/000168316826004871/sonoma_i10k-033126.htm#582508 Filing: 000168316826004871 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

104 filings · 5,162 latest values · 5,162 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001367083, 1367083, SNOA, edgar:1367083, ocls

Also known as Oculus Innovative Sciences, Inc., SONOMA PHARMACEUTICALS, INC, SONOMA PHARMACEUTICALS, INC., Sonoma Pharmaceuticals, Inc.

SONOMA PHARMACEUTICALS, INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2026 2025-04-01 – 2026-03-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation